[{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LY01005","moa":"Goserelin receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY01005","moa":"Goserelin receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2-like dopamine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alliance for Clinical Trials in Oncology | Evolution Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Alliance for Clinical Trials in Oncology | Evolution Research Group","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Alliance for Clinical Trials in Oncology | Evolution Research Group"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LY03003","moa":"Rotigotine receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY01005","moa":"Goserelin receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LY09004","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY01015","moa":"Trastuzumab receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"LY-CovMab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BA1202","moa":"CEA","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY01008","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BA1106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LPM3480392","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LPM3480392","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BA1302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BA1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Alvogen"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cap Alter Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cap Alter Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cap Alter Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ DCH Auriga"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distribution Solutions"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distriphil"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ ICI Pakistan Limited"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor||Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zuellig Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Toludesvenlafaxine HCl","moa":"Serotonin\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ansofaxine HCl","moa":"5-HT\/norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Toludesvenlafaxine HCl","moa":"Serotonin\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM3770164","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LPM3770164","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM3770164","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM6690176","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY03017","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM3770164","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY03017","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"LY01011","moa":"TNFSF11","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY06006","moa":"Denosumab receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Undisclosed","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Luye Pharma \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Parexel"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY06006","moa":"Denosumab receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Exeltis"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Myung In Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Myung In Pharm"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Zambon Group SpA","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zambon Group SpA"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2-like dopamine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Parexel"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM3480392","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM3480392","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY010616","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LY03010","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LY03009","moa":"Rivastigmine receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LY03003","moa":"Rotigotine receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LY03003","moa":"Rotigotine receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"SocraTec R&D GmbH | SocraMetrics GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RID-TDS","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ SocraTec R&D GmbH | SocraMetrics GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ SocraTec R&D GmbH | SocraMetrics GmbH"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY03020","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BA1105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BA1202","moa":"CEA","graph1":"Oncology","graph2":"Preclinical","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Luye Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Luye Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 15, 2025

                          Lead Product(s) : BA1301

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Erzofri (paliperidone palmitate) is an 5-HT2a and D2 receptor antagonist which is indicated for the treatment of schizophrenia and schizoaffective disorder.

                          Product Name : Erzofri

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 06, 2025

                          Lead Product(s) : Paliperidone Palmitate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : LY03017

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : LPM3770164

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Meibirui (paliperidone palmitate injection) has been approved for marketing by China’s NMPA, to be used for the acute and maintenance treatment of schizophrenia.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 06, 2024

                          Lead Product(s) : Paliperidone Palmitate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : BA1302

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 16, 2024

                          Lead Product(s) : LY03020

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Erzofri (paliperidone palmitate) is an 5-HT2a and D2 receptor antagonist which is indicated for the treatment of schizophrenia and schizoaffective disorder.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 28, 2024

                          Lead Product(s) : Paliperidone Palmitate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 11, 2024

                          Lead Product(s) : Lurbinectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 25, 2024

                          Lead Product(s) : LPM3770164

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank